Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)

The Election Committee of Vitrolife, which was appointed in accordance with the resolution of the Annual General Meeting on April 27, 2011, consists of:

Henrik Blomquist, representing Bure Equity AB
Johan Ståhl, representing Lannebo Fonder
Martin Lewin, representing Eccenovo AB
Patrik Tigerschiöld, Chairman of the Board

The Election Committee proposes the following to the Annual General Meeting of Vitrolife that will take place on Thursday April 19, 2012:

-  that the Chairman of the meeting shall be Patrik Tigerschiöld.

-  that the members of the Board shall be six in number.

-  that the Board fees shall be SEK 770,000, of which SEK 220,000 to the Chairman of the Board and SEK 110,000 to each of the other members of the Board. The amounts include remuneration for committee work. The proposal means that Board fees are unchanged.

-  re-election of the Board members Patrik Tigerschiöld, Fredrik Mattsson, Maris Hartmanis, Tord Lendau and Barbro Fridén and election of the new Board member Carsten Browall (executive Chairman of the Board of Unfors RaySafe AB). Madeleine Olsson-Eriksson has declined re-election. Patrik Tigerschiöld is proposed for re-election as Chairman of the Board.

that a new Election Committee be set up for the Annual General Meeting of 2013. It is proposed that the Election Committee is appointed in the same way as previously, whereby the Chairman of the Board contacts the three largest registered shareholders or otherwise known owners at the end of the third quarter of 2012 and asks them to appoint one member each. The three members who are appointed and the Chairman of the Board constitute the Election Committee. The Election Committee appoints a Chairman internally.

Queries should be addressed to:

Henrik Blomquist, Chairman of the Election Committee, phone +46 8 614 00 20
Patrik Tigerschiöld, Chairman of the Board, phone +46 8 614 00 20

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on March 16, 2012 at 11:00 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.


Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: Website:


About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 370 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.


Documents & Links